Upstream Bio, Inc. (UPB)
$4.70+3.30%Close
SELLCRISIS · day 30
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $256M
- Beta
- 1.39
- P/E (TTM)
- -1.58
- Short % float
- 22.48%
- Days to cover
- 7.7
- SI change
- +0.5%
- 1W
- -6.75%
- 1M
- -18.26%
- vs SPY 1W
- -7.91%
- vs SPY 1M
- -21.25%
Industry peers
FMP comparable companies · ranked by market cap
- SYRESELLSpyre Therapeutics, Inc.$7.4BCRISISQ 10$85.69+7.25%
- TERNTerns Pharmaceuticals, Inc.$6.1B$52.95
- RLAYSELLRelay Therapeutics, Inc.$3.9BRECOVERYQ 3$17.88+2.70%
- AMLXSELLAmylyx Pharmaceuticals, Inc.$3.1BCRISISQ 8$28.14+3.46%
- PHVSSELLPharvaris N.V.$2.2BCRISISQ 15$31.10-0.06%
- NVAXBUYNovavax, Inc.$2.1BRECOVERYQ 10$12.75+15.80%
- NTLABUYIntellia Therapeutics, Inc.$1.8BRECOVERYQ 4$13.07+3.73%
- ZBIOSELLZenas BioPharma, Inc.$1.7BCRISISQ 15$27.26+3.89%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.5BCRISISQ 17$16.99+0.53%
- WVESELLWave Life Sciences Ltd.$682MCRISISQ 7$3.46-0.29%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on UPB?
- LOPJLB’s latest quantitative signal on Upstream Bio, Inc. (UPB) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is UPB in?
- Upstream Bio, Inc. (UPB) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Upstream Bio, Inc. (UPB) do?
- Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively develo…